Staged transcatheter treatment of portal hypoplasia and congenital portosystemic shunts in children

Bruckheimer, E.; Dagan, T.; Atar, E.; Schwartz, M.; Kachko, L.; Superina, R.; Amir, G.; Shapiro, R.; Birk, E.

Cardiovasc Intervent Radiol. 2013 Feb 26; 36(6):1580-5


PURPOSE: Congenital portosystemic shunts (CPSS) with portal venous hypoplasia cause hyperammonemia. Acute shunt closure results in portal hypertension. A transcatheter method of staged shunt reduction to afford growth of portal vessels followed by shunt closure is reported. METHODS: Pressure measurements and angiography in the CPSS or superior mesenteric artery (SMA) during temporary occlusion of the shunt were performed. If vessels were diminutive and the pressure was above 18 mmHg, a staged approach was performed, which included implantation of a tailored reducing stent to reduce shunt diameter by ~50 %. Recatheterization was performed approximately 3 months later. If the portal pressure was below 18 mmHg and vessels had developed, the shunt was closed with a device. RESULTS: Six patients (5 boys, 1 girl) with a median age of 3.3 (range 0.5-13) years had CPSS portal venous hypoplasia and hyperammonemia. Five patients underwent staged closure. One patient tolerated acute closure. One patient required surgical shunt banding because a reducing stent could not be positioned. At median follow-up of 3.8 (range 2.2-8.4) years, a total of 21 procedures (20 transcatheter, 1 surgical) were performed. In all patients, the shunt was closed with a significant reduction in portal pressure (27.7 +/- 11.3 to 10.8 +/- 1.8 mmHg; p = 0.016), significant growth of the portal vessels (0.8 +/- 0.5 to 4.0 +/- 2.4 mm; p = 0.037), and normalization of ammonia levels (202.1 +/- 53.6 to 65.7 +/- 9.6 mumol/L; p = 0.002) with no complications. CONCLUSION: Staged CPSS closure is effective in causing portal vessel growth and treating hyperammonemia.

Read More on PubMed